Clinical Trials Directory

Trials / Completed

CompletedNCT00189748

A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-

An Extension Study of the Patients Enrolled in Acute Graft Versus Host Disease (GVHD) Prophylaxis Study (Protocol No. FJ-506E-BT01) to Assess Safety and Efficacy of GVHD Prophylaxis of a Tacrolimus New Oral Formulation (MR4).

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
Astellas Pharma Inc · Industry
Sex
All
Age
20 Years – 54 Years
Healthy volunteers
Not accepted

Summary

To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)

Conditions

Interventions

TypeNameDescription
DRUGTacrolimus

Timeline

Start date
2004-08-01
First posted
2005-09-19
Last updated
2006-09-20

Locations

4 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT00189748. Inclusion in this directory is not an endorsement.